Nr5a2 Nuclear Receptor Reprogramming Somatic Cells

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for reprogramming somatic cells to a pluripotent state, such as using Oct4, Sox2, Klf4, and c-Myc, are inefficient and require the presence of Oct4, which is critical but difficult to replace with other transcription factors.

Innovation Solution

The use of nuclear receptors, specifically Nr5a2 and Nr5a1, from subfamily 5, which can replace Oct4 and enhance reprogramming efficiency by introducing polynucleotides encoding these receptors along with Sox genes and myc family genes to induce pluripotency in somatic cells.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If Oct4 is used to reprogram somatic cells to a pluripotent state, then pluripotency is achieved, but reprogramming efficiency is low and Oct4 cannot be replaced by other transcription factors

Engineering Contradiction:
Improvepluripotency inductionVSAvoidreprogramming efficiency
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent changes the transcriptional parameters by replacing Oct4 with Nr5a2, a nuclear receptor from subfamily 5. This substitution alters the transcriptional regulation mechanism while achieving the same functional outcome of inducing pluripotency, thereby improving reprogramming efficiency without sacrificing reliability

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Nr5a2 acts as an intermediary transcription factor that can substitute for Oct4 in the reprogramming process. By introducing this intermediate factor, the patent enables alternative pathways to achieve pluripotency induction, resolving the contradiction between reliability and productivity

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If Oct4 is used to induce pluripotency, then pluripotent cells are generated, but the process is time-consuming and inefficient

Engineering Contradiction:
Improvepluripotent cell generationVSAvoidreprogramming time
Core Design Contradiction:
ReliabilityVSLoss of time

Solution Approach 1:

By changing the transcriptional parameters from Oct4-based regulation to Nr5a2-based regulation, the patent accelerates the reprogramming process. Nr5a2 exhibits enhanced transcriptional activity that reduces the time required to achieve pluripotency induction while maintaining reliable generation of pluripotent cells

Inventive Principle:
Principle #35Parameter changes

3Reliability

If traditional reprogramming factors (Oct4, Sox2, Klf4, c-Myc) are used, then reprogramming can be achieved, but the method is complex and requires multiple factors

Engineering Contradiction:
Improvereprogramming capabilityVSAvoidnumber of transcription factors
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts and replaces the critical Oct4 factor with Nr5a2, simplifying the reprogramming system. By removing the requirement for Oct4 and substituting it with a single nuclear receptor that can functionally replace it, the complexity of the transcription factor组合 is reduced while maintaining reprogramming capability

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

Nr5a2 exhibits universal functionality by being able to replace Oct4's role in pluripotency induction. This multi-functional nuclear receptor can perform the essential functions previously requiring multiple factors, thereby reducing system complexity while preserving reliability

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS9963682B2Nuclear receptor and mutant thereof and the use of the same in the reprogramming of cells
Publication Date: 2018.05.08 AGENCY FOR SCI TECH & RES
  • US9963682B2 patent drawing
  • US9963682B2 patent drawing
  • US9963682B2 patent drawing

AI summary

According to the invention there is provided methods for inducing pluripotent stem cells in vitro, vectors and compositions for producing the same and methods for using the induced pluripotent stem cell for treating a patient in need of a pluripotent stem cell treatment.